Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial

Abstract Background The development of systemic therapy, including targeted drugs and immune checkpoint inhibitors, has significantly improved the prognosis of patients with advanced unresectable hepatocellular carcinoma (uHCC). Hepatic arterial infusion chemotherapy (HAIC) has been gradually applie...

Full description

Saved in:
Bibliographic Details
Main Authors: Kugeluke Yalikun, Zhongchao Li, Jianxin Zhang, Zhibin Chang, Mingming Li, Zhicheng Sun, Zhaogang Liu, Yue Yang, Lei Xu, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Kai Cui, Xuetao Shi, Bo Zhang, Lei Zhao
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Apatinib
Camrelizumab
Hepatic arterial infusion chemotherapy
Unresectable hepatocellular carcinoma
Conversion therapy
Online Access:https://doi.org/10.1186/s12885-025-14250-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14250-5

Similar Items